HIMS — Hims & Hers Health, Inc.

HIMS & HERS Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $618 million, up 28% year-over-year.
• Full Year Revenue: $2.35 billion, representing a 59% increase year-over-year.
• Subscribers: Over 2.5 million, with 65% utilizing personalized treatments.
• Monthly Revenue per Subscriber: Increased 11% year-over-year to $83.
• Adjusted EBITDA: $318 million for 2025, an increase of nearly 80% year-over-year, with a margin of 14%.
• Net Income: $128 million for the full year.
• Free Cash Flow: $57 million generated in 2025, ending the year with $929 million in cash and investments.

2. Strategic Updates and Business Highlights

• Expansion of Offerings: Launched new services in hormone therapies (low testosterone, menopause) and Labs, with expectations of each reaching $100 million in revenue soon.
• International Growth: Significant expansion into markets like the U.K., Germany, Canada, Australia, and Japan, with international revenue growing almost 400% year-over-year to $134 million.
• Acquisitions: Completed acquisitions of ZAVA and Livewell, and announced an agreement to acquire Eucalyptus to enhance international presence.
• Technological Investments: Focus on AI, diagnostics, and personalized care, with plans to integrate wearables and home testing technologies.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected between $600 million and $625 million, a year-over-year increase of 2% to 7%.
• 2026 Full Year Revenue Guidance: Anticipated between $2.7 billion and $2.9 billion, representing a 15% to 24% increase.
• Adjusted EBITDA for 2026: Projected between $300 million and $375 million, with an adjusted EBITDA margin of 12%.
• International Revenue Contribution: Expected at least $200 million from international markets in 2026.

4. Bad News, Challenges, or Points of Concern

• GLP-1 Treatment Scrutiny: Potential regulatory challenges surrounding compounded GLP-1s could impact growth; currently, only a small portion of subscribers utilize these treatments.
• Shipping Cadences Impact: Anticipated $65 million revenue headwind in Q1 2026 due to changes in shipping processes for weight loss products.
• Marketing Costs: Increased investment in marketing, particularly from a Super Bowl commercial, may pressure EBITDA in the short term.
• International Market Margins: New international markets expected to run near breakeven initially, with margin expansion anticipated only in the longer term.

5. Notable Q&A Insights

• International Strategy: The company aims to unify the Hims & Hers brand across key markets and targets $1 billion in incremental international revenue in the coming years.
• Regulatory Environment: Management is actively engaging with regulatory bodies to address concerns and ensure compliance.
• Durability of Weight Loss Business: Despite scrutiny, management believes in the long-term viability of the weight loss segment, supported by a growing range of treatment options.
• Investment Focus: Future investments will prioritize technology, personalized care, and expanding the product offering to enhance customer engagement and retention.

Overall, Hims & Hers showcased strong financial growth and strategic expansion plans while addressing potential regulatory challenges and market dynamics. The company remains focused on evolving its offerings and enhancing customer experiences as it looks to achieve ambitious long-term revenue and profitability targets.